Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Recent Posts
- Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent
- Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
- Viewpoint Molecular Targeting Announces Two New Grant Awards of $2 Million Each
- Viewpoint Molecular Targeting Announces Appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer
- Viewpoint Molecular Targeting Announces VMT- -NET Granted U.S. FDA Fast Track Destination for the Treatment of Neuroendocrine Tumors
Recent Comments